IMNM as reported
Immunome, Inc. reported $12M of revenue over the trailing twelve months, +11% on the year before. 8 reported series are charted on this page, each one as filed.
$12M
Revenue, trailing twelve months · to Q1 2026 · +11% against the twelve months before
- Net Income
- −$225M
Net Income · +9.5% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$206M
Free Cash Flow · +27% year on year · trailing twelve months to Q1 2026
- Op Margin
- −1989%
Op Margin · trailing twelve months to Q3 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $12M | +11% | Q1 2026 |
| Net Income | −$225M | +9.5% | Q1 2026 |
| EPS | −$2.38 | −25% | Q1 2026 |
| Op Margin | −1989% | n/a | Q3 2025 |
| Net Margin | −1895% | n/a | Q3 2025 |
| ROE | −59% | n/a | Q1 2026 |
| ROA | −53% | n/a | Q1 2026 |
| Free Cash Flow | −$206M | +27% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Immunome, Inc. (IMNM) - Revenue & ProfitRevenue & ProfitImmunome, Inc. (IMNM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com